These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

402 related articles for article (PubMed ID: 21757968)

  • 1. Pancreatogenic diabetes: special considerations for management.
    Cui Y; Andersen DK
    Pancreatology; 2011; 11(3):279-94. PubMed ID: 21757968
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Diabetes and pancreatic cancer.
    Cui Y; Andersen DK
    Endocr Relat Cancer; 2012 Oct; 19(5):F9-F26. PubMed ID: 22843556
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The nutritional management of type 3c (pancreatogenic) diabetes in chronic pancreatitis.
    Duggan SN; Ewald N; Kelleher L; Griffin O; Gibney J; Conlon KC
    Eur J Clin Nutr; 2017 Jan; 71(1):3-8. PubMed ID: 27406162
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Type-3c Diabetes Mellitus, Diabetes of Exocrine Pancreas - An Update.
    Bhattamisra SK; Siang TC; Rong CY; Annan NC; Sean EHY; Xi LW; Lyn OS; Shan LH; Choudhury H; Pandey M; Gorain B
    Curr Diabetes Rev; 2019; 15(5):382-394. PubMed ID: 30648511
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A novel peptide nanomedicine for treatment of pancreatogenic diabetes.
    Banerjee A; Onyuksel H
    Nanomedicine; 2013 Aug; 9(6):722-8. PubMed ID: 23347897
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment with incretins does not increase the risk of pancreatic diseases compared to older anti-hyperglycaemic drugs, when added to metformin: real world evidence in people with Type 2 diabetes.
    Montvida O; Green JB; Atherton J; Paul SK
    Diabet Med; 2019 Apr; 36(4):491-498. PubMed ID: 30306620
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Challenges of Managing Type 3c Diabetes in the Context of Pancreatic Resection, Cancer and Trauma.
    Wayne CD; Benbetka C; Besner GE; Narayanan S
    J Clin Med; 2024 May; 13(10):. PubMed ID: 38792534
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Diabetes mellitus secondary to pancreatic diseases (Type 3c)--are we neglecting an important disease?
    Ewald N; Bretzel RG
    Eur J Intern Med; 2013 Apr; 24(3):203-6. PubMed ID: 23375619
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pancreatic polypeptide administration enhances insulin sensitivity and reduces the insulin requirement of patients on insulin pump therapy.
    Rabiee A; Galiatsatos P; Salas-Carrillo R; Thompson MJ; Andersen DK; Elahi D
    J Diabetes Sci Technol; 2011 Nov; 5(6):1521-8. PubMed ID: 22226275
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment with metformin and a dipeptidyl peptidase-4 inhibitor elevates apelin levels in patients with type 2 diabetes mellitus.
    Fan Y; Zhang Y; Li X; Zheng H; Song Y; Zhang N; Shen C; Fan X; Ren F; Shen J; Ren G; Yang J
    Drug Des Devel Ther; 2015; 9():4679-83. PubMed ID: 26316706
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Type 3c (pancreatogenic) diabetes mellitus secondary to chronic pancreatitis and pancreatic cancer.
    Hart PA; Bellin MD; Andersen DK; Bradley D; Cruz-Monserrate Z; Forsmark CE; Goodarzi MO; Habtezion A; Korc M; Kudva YC; Pandol SJ; Yadav D; Chari ST;
    Lancet Gastroenterol Hepatol; 2016 Nov; 1(3):226-237. PubMed ID: 28404095
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New combination treatments in the management of diabetes: focus on sitagliptin-metformin.
    Green J; Feinglos M
    Vasc Health Risk Manag; 2008; 4(4):743-51. PubMed ID: 19065992
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of insulin glargine added to a fixed-dose combination of metformin and a dipeptidyl peptidase-4 inhibitor: results of the GOLD observational study.
    Seufert J; Pegelow K; Bramlage P
    Vasc Health Risk Manag; 2013; 9():711-7. PubMed ID: 24259985
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pancreatic exocrine insufficiency, diabetes mellitus and serum nutritional markers after acute pancreatitis.
    Vujasinovic M; Tepes B; Makuc J; Rudolf S; Zaletel J; Vidmar T; Seruga M; Birsa B
    World J Gastroenterol; 2014 Dec; 20(48):18432-8. PubMed ID: 25561813
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Second-line therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy: a systematic review and mixed-treatment comparison meta-analysis.
    McIntosh B; Cameron C; Singh SR; Yu C; Ahuja T; Welton NJ; Dahl M
    Open Med; 2011; 5(1):e35-48. PubMed ID: 22046219
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pancreatic Cancer-Associated Diabetes is Clinically Distinguishable From Conventional Diabetes.
    Yoon BH; Ang SM; Alabd A; Furlong K; Yeo CJ; Lavu H; Winter JM
    J Surg Res; 2021 May; 261():215-225. PubMed ID: 33453685
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical signature and pathogenetic factors of diabetes associated with pancreas disease (T3cDM): a prospective observational study in surgical patients.
    Balzano G; Dugnani E; Pasquale V; Capretti G; Radaelli MG; Garito T; Stratta G; Nini A; Di Fenza R; Castoldi R; Staudacher C; Reni M; Scavini M; Doglioni C; Piemonti L
    Acta Diabetol; 2014 Oct; 51(5):801-11. PubMed ID: 24974302
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone.
    Charbonnel B; Karasik A; Liu J; Wu M; Meininger G;
    Diabetes Care; 2006 Dec; 29(12):2638-43. PubMed ID: 17130197
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risks of cardiovascular diseases associated with dipeptidyl peptidase-4 inhibitors and other antidiabetic drugs in patients with type 2 diabetes: a nation-wide longitudinal study.
    Ou HT; Chang KC; Li CY; Wu JS
    Cardiovasc Diabetol; 2016 Mar; 15():41. PubMed ID: 26932742
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Incretins: their physiology and application in the treatment of diabetes mellitus.
    Tasyurek HM; Altunbas HA; Balci MK; Sanlioglu S
    Diabetes Metab Res Rev; 2014 Jul; 30(5):354-71. PubMed ID: 24989141
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.